Read-Gene SA
4.84
PLN
-0.16
(-3.20%)
ISIN
PLRADGN00014
Return %
Stock
S&P 500
1Y
-19.06
14.20
3Y
44.91
81.12
5Y
89.80
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jan Lubinski
- Full Time Employees
- 22
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Szczecin Poland
- IPO Date
- Feb 12, 2009
- Website
- read-gene.com
- Similar Companies
- Business
- Read-Gene S.A. is a biotechnology and personalized medicine company that specializes in cancer genetics, oncological risk assessment, chemoprevention, and specialized clinical trial services. The company develops and commercializes innovative diagnostic and preventive solutions based on the correlation between genetic profiles, micronutrient levels, and oncological disease risks. Read-Gene organizes its commercial activities into three core business segments: Genetic Testing, Chemoprevention, and Clinical Trials. The Genetic Testing segment offers advanced DNA testing services designed to identify genetic predispositions to various hereditary malignancies, including breast, ovarian, colorectal, and prostate cancers; comprehensive carrier screening panels; personalized oncological risk-profiling assays; and digital consultation and genetic counseling platforms for patients and healthcare providers. The Chemoprevention segment develops, manufactures, and distributes specialized dietary supplements, nutritional formulations, and functional food products engineered with strictly controlled concentrations of critical trace elements and vitamins; personalized micronutrient optimization programs; and therapeutic dietary management regimens designed to reduce the risk of oncological onset and disease progression. The Clinical Trials segment provides specialized contract research services to corporate clients across the pharmaceutical, biotechnology, medical device, and chemical sectors; genetic patient stratification and recruitment utilizing a proprietary biobank and clinical database of over two million patient records and 700,000 DNA samples; and clinical study monitoring, biobanking, and data management services. Founded in 2005 and headquartered in Szczecin (Dobra), Poland, Read-Gene operates as a subsidiary of Gen-Pat-Med Sp. z o.o. and maintains an active scientific collaboration with the International Hereditary Cancer Center at the Pomeranian Medical University. The company serves individual patients, genetic advisory centers, and international biotechnology and pharmaceutical corporations throughout Poland, Europe, and global healthcare markets. In recent developments, Read-Gene has advanced its intellectual property portfolio and diagnostic research pipeline in the field of oncological microelements (onco-elements). The company secured patent approval from the Polish Patent Office for its proprietary method of determining cancer risk, published clinical research validating correlations between blood selenium concentrations and patient mortality outcomes, and expanded its commercial test offerings and strategic clinical partnerships for biomarker-based patient selection in targeted oncology trials.